P-x-x Containing (x Is Chalcogen) Patents (Class 514/109)
-
Publication number: 20030206885Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.Type: ApplicationFiled: May 5, 2003Publication date: November 6, 2003Inventor: John W. Hadden
-
Publication number: 20030203879Abstract: The invention relates to the calcium complex of [[(4R)-4-[bis[(carboxy-.kappa.O)methyl]amino-.kappa.N]-6,9-bis[(carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid.kappa.N6,.kappa. N9,.kappa.011]1-oxidato(6-)]-, tetrahydrogen (MS-325) and its salts, pharmaceutical agents that contain these complexes, for the production of agents for the reduction of effects that are caused by heavy metals as well as processes for their production.Type: ApplicationFiled: January 15, 2003Publication date: October 30, 2003Applicant: Schering AGInventors: Johannes Platzed, Ulrich Nieballa, Guenter Michl
-
Publication number: 20030190687Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: March 5, 2003Publication date: October 9, 2003Inventors: Tong Zhou, Kimihisa Ichikawa, Robert P Kimberly, William J Koopman
-
Patent number: 6630512Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: October 23, 2001Date of Patent: October 7, 2003Assignee: Biogen, Inc.Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao, Julio Hernan Cuervo, Juswinder Singh
-
Patent number: 6627660Abstract: Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.Type: GrantFiled: November 16, 1999Date of Patent: September 30, 2003Assignee: New River Pharmaceuticals Inc.Inventors: Thomas Piccariello, Anne F. LeClercq
-
Publication number: 20030181393Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.Type: ApplicationFiled: March 28, 2003Publication date: September 25, 2003Inventors: Theodore J. Lampidis, Waldemare Priebe
-
Patent number: 6624152Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: August 22, 2001Date of Patent: September 23, 2003Assignee: Biogen, Inc.Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao
-
Publication number: 20030170234Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.Type: ApplicationFiled: April 4, 2003Publication date: September 11, 2003Applicant: GENENTECH, INC.Inventor: Susan D. Hellmann
-
Patent number: 6566304Abstract: The invention relates to use of (a) compounds of phosphorus containing at least partly lipophilic organic radicals together with (b) urea and/or urea derivatives in selected quantity ratios of (a) to (b) as a soil additive for biologically controlling plant-parasitic soil nematodes by strengthening the correspondingly antagonistic soil potential, more particularly by strengthening the growth of antagonistic and/or nematicidal rhizosphere bacteria and/or corresponding mycorrhiza strains—and at the same time strengthening the growth of cultivated plants in soil. The multicomponent mixtures which strengthen bacterial growth are preferably introduced into the region of the plant roots in the form of an aqueous preparation using plant-compatible emulsifiers before and/or during plant growth. Components (a) and (b) are used in such quantity ratios that the ratio by weight of C to N is no higher than 6:1 and preferably no higher than 5:1.Type: GrantFiled: February 6, 2001Date of Patent: May 20, 2003Assignee: Cognis Deutschland GmbHInventors: Doris Bell, Bettina Kopp-Holtwiesche, Stephan Von Tapavicza
-
Patent number: 6509325Abstract: The present invention provides a method for treating a subject infected with a mammalian pathogenic fungus which uses melanin in virulence, by administering to the subject an amount of glyphosate effective to treat the infection. The present invention further provides a method for inhibiting proliferation of a mammalian pathogenic fungus which uses melanin in virulence, by contacting the fungus with an amount of glyphosate effective to inhibit the proliferation of the fungus. Additionally, the present invention further provides a method for inhibiting melanogenesis in a microorganism which produces melanin, by contacting the microorganism with an amount of glyphosate effective to inhibit melanogenesis in the microorganism.Type: GrantFiled: May 2, 2000Date of Patent: January 21, 2003Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Joshua D. Nosanchuk, Arturo Casadevall, Rafael Ovalle
-
Patent number: 6489312Abstract: The present invention provides novel pharmaceutical compositions comprising aminoalkyl phosphorothioate compounds in combination with surfactants, hydrotropes and chelating agents. The compositions are well-suited for subcutaneous administration.Type: GrantFiled: June 15, 1999Date of Patent: December 3, 2002Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Javad M. Zadei
-
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
Patent number: 6476006Abstract: The present invention provides compacted pharmaceutical composition for oral administration to a patient which expands upon contact with gastric fluid to retain a dosage form in the patient's stomach for an extended period of time, the formulation comprising a non-hydrated hydrogel, a superdisintegrant and tannic acid. The present invention further provides a pharmaceutical dosage form containing an active ingredient, and the compacted pharmaceutical composition. The invention further provides a dosage form suitable for delivering a therapeutic bis-phosphonate such as alendronate to the stomach of a patient over and extended period.Type: GrantFiled: January 26, 2001Date of Patent: November 5, 2002Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Moshe Flashner-Barak, Vered Rosenberger, Mazal Dahan, Yitzhak Lerner -
Patent number: 6440443Abstract: Pesticidal formulations of cadusafos are provided. An aqueous capsule suspension is provided, containing from about 150 to about 360 grams of cadusafos per liter of formulation and having lower mammalian toxicity than aqueous cadusafos microemulsion formulations is prepared by interfacial polymerization of a first polyfunctional compound, such as a polymethylene polyphenyl isocyanate, with a second polyfunctional compound, such as a polyfunctional amine or mixtures of polyfunctional amines, in an aqueous phase optionally containing from about 0.05 to about 0.50 xanthan gum viscosity modifier/stabilizer. A granular form of the microencapsulated cadusafos is also provided. Several such formulations and the method of their preparation are described.Type: GrantFiled: July 29, 1999Date of Patent: August 27, 2002Inventors: Fui-Tseng H. Lee, Paul Nicholson, Janos Szamosi, William T. Sommer
-
Patent number: 6399592Abstract: Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM 210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.Type: GrantFiled: June 23, 1997Date of Patent: June 4, 2002Assignee: Merck & Co., Inc.Inventor: Donna T. Whiteford
-
Patent number: 6372728Abstract: The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an absorption enhancing agent essentially consisting of a medium chain glyceride or a mixture of medium chain glycerides. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.Type: GrantFiled: October 29, 1998Date of Patent: April 16, 2002Assignee: AstraZeneca ABInventor: Anna-Lena Ungell
-
Patent number: 6358936Abstract: It is shown that the potency of anti-cancer drugs, here exemplified by doxorubicin, can be increased by the use of polyunsaturated fatty acid amides and in particular specific combinations of such compounds, forming complexes with doxorubicin. Further, a modified form of doxorubicin is presented.Type: GrantFiled: January 30, 2001Date of Patent: March 19, 2002Assignee: Ardenia Investments, Ltd.Inventor: Oleg Strelchenok
-
Patent number: 6352970Abstract: This invention relates to methods for treating bone loss in a mammal by administering to the mammal a therapeutically effective amount of leptin or a leptin mimetic. This invention also relates to methods for treating bone fracture, enhancing bone healing following facial reconstruction, maxillary reconstruction or madibular reconstruction, enhancing long bone extension, enhancing the healing rate of a bone graft, enhancing prosthetic growth and inducing vertebral synostosis by administering a therapeutically effective amount of leptin or a leptin mimetic. This invention further relates to methods and compositions comprising leptin or a leptin mimetic and estrogen, a selective estrogen receptor modulator or a bisphonate for treating the above-recited diseases and conditions.Type: GrantFiled: February 19, 1999Date of Patent: March 5, 2002Assignee: Pfizer Inc.Inventors: HuaZhu Ke, Claire M. Steppan, Andrew Gordon Swick
-
Patent number: 6329354Abstract: Methods of treatment for osteoporosis in a human or other animal subject, comprising: administering a bone-active phosphonate to said subject, at a level of at least about 0.1 LED per day of said treatment; and administering an estrogen hormone to said subject at a level of from about 0.2 to about 0.8 LED per day of said treatment. The bone-active phosphonate is preferably a bisphosphonate, or a phosphonoalkyl phosphonate.Type: GrantFiled: January 25, 1993Date of Patent: December 11, 2001Assignee: The Procter & Gamble CompanyInventor: Jocelyn Elaine McOsker
-
Patent number: 6306840Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: January 23, 1995Date of Patent: October 23, 2001Assignee: Biogen, Inc.Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao
-
Patent number: 6303588Abstract: Methods are disclosed for correcting biological information transfer in a patient in need of such therapy which comprise administration to a patient of a composition comprising a therapeutically effective amount of a biocomplex comprising at least one bioactive agent from each of the three informational blocks of biological information transfer, each agent being present in an amount sufficient to correct the biological information transfer of the patient under treatment and resulting in the resumption of normal cell metabolism, said amount being less than the buffering amount of said agent; together with a carrier therefor.Type: GrantFiled: January 12, 1999Date of Patent: October 16, 2001Inventor: Michael M. Danielov
-
Patent number: 6291441Abstract: This invention relates to a method of treating patients suffering from the inflammatory bowel disorders. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: September 27, 2000Date of Patent: September 18, 2001Inventors: Frederick H. Hausheer, Seetharamulu Peddaiahgari
-
Patent number: 6218435Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA.Type: GrantFiled: July 17, 1998Date of Patent: April 17, 2001Inventors: James Henry, Gurpreet Ahluwalia, Douglas Shander
-
Patent number: 6117856Abstract: Bisphosphonates inhibit bone resorption associated with periodonatal or orthopedic surgery when applied topically to the bone. A novel formulation for topical application contains a gelatin matrix which is soaked in a solution containing a bone absorption inhibiting effective amount of a bisphosphonate or a pharmaceutically acceptable salt.Type: GrantFiled: July 15, 1998Date of Patent: September 12, 2000Inventors: Itzhak Binderman, Avinoam Yaffe
-
Patent number: 6087349Abstract: A method is provided by blocking or preventing the prenylation of CAAX box containing proteins including ras oncogene products thereby preventing and/or treating ras-related tumors which includes the step of administering a therapeutically effective amount of a protein-prenyl transferase inhibitor.Type: GrantFiled: May 6, 1998Date of Patent: July 11, 2000Assignee: E. R. Squibb & Sons, Inc.Inventors: Scott A. Biller, Mariano Barbacid, Eric M. Gordon, David R. Magnin, Chester A. Meyers, Veeraswamy Manne
-
Patent number: 6017905Abstract: The present invention is directed to compounds useful for the regulation of cholesterol of Formula I, methods for using them and pharmaceutical compositions thereof, ##STR1## wherein Ar and Ar.sup.1 are each independently selected from unsubstituted or substituted phenyl which substituents are from 1-5 in number and are each independently selected from alkyl, alkoxy, hydroxy, halogen, nitro, trifluoromethyl, COOH, and COOalkyl;X is --NH--, --O--, --S--, or --(CH.sub.2).sub.0-4 --, andR is hydrogen, alkyl, or phenyl.Type: GrantFiled: June 9, 1998Date of Patent: January 25, 2000Assignee: Warner-Lambert CompanyInventors: William Howard Roark, Bruce David Roth
-
Patent number: 5985859Abstract: A method of inhibiting bacterial sialidase comprising administering to a subject an inhibiting effective amount of a compound of formula I: ##STR1## wherein A is CO.sub.2 H, PO.sub.2 H, or SO.sub.2 H; B is N; R.sub.1 and R.sub.2 are H; R.sub.3 and R.sub.4 are, independently, H, OH, NO.sub.2, guanidino, or alkyl or alkenyl of from 1 to 3 carbons where the alkyl or alkenyl is unsubstituted or is substituted, independently, with one or more of OH, NH2, or halide; R.sub.5 is H; and R.sub.6 is COCH.sub.3, or COCI.sub.3 ; or an analog, pharmaceutically acceptable salt, derivative, or mixture thereof. A method of preventing a bacterial or trypanosomal infection using the compounds of formula I. A method of treating a bacterial or trypanosomal infection using the compounds of formula I. A pharmaceutical composition comprising a pharmaceutically acceptable carrier admixed with an inhibiting effective amount of a compound of formula I.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignee: The University of AlabamaInventor: Ming Luo
-
Patent number: 5972349Abstract: Polyribosylribitol phosphate oligosaccharides are produced in a multistep process. The compound of the formula: ##STR1## wherein R.sub.1 is a first protecting group and R.sub.2 is a second protecting group, is coupled to a solid polyethylene glycol monomethyl ether (PEG) support. Following removal of the first protecting group, the resulting compound is coupled with a repeating unit for chain elongation of the formula: ##STR2## The protecting group is removed from the phosphorus atom and the steps of removing the first protecting group, coupling with the repeating unit is repeated until the desired number of repeating units in the oligomer has been terminated. The oligomer then is terminated with a chain terminating molecule of the formula: ##STR3## wherein m is an integer and R.sub.3 is a third protecting group.Type: GrantFiled: June 7, 1995Date of Patent: October 26, 1999Assignee: Connaught Laboratories LimitedInventors: Pele Chong, Ali Kandil, Charles Sia, Michel Klein
-
Patent number: 5968498Abstract: The freshness of meat, vegetables and fruits in a refrigerator or food storage box can be retained for a long period of time by using (1) a freshness retaining gel composition which comprises a freshness retainer component comprising an isothiocyanic acid compound and an aliphatic carboxylic acid or (2) a freshness retaining gel composition which comprises a freshness retainer component comprising an isothiocyanic acid compound, a nonionic surfactant or a fatty acid ester, and a gelling agent.Type: GrantFiled: January 28, 1998Date of Patent: October 19, 1999Inventors: Toru Okada, Kenji Kuranari, Yukari Mihara
-
Patent number: 5955092Abstract: N-substituted fatty acid amides which sufficiently inhibit LRAT or ARAT catalyzed esterification of retinol into inactive retinyl esters, have the same effect on keratinocytes as retinoic acid. Thus, effects of the retinol or retinyl esters in combination with N-substituted fatty acid amides are analogous to treatment with retinoic acid.Type: GrantFiled: September 27, 1996Date of Patent: September 21, 1999Assignee: Elizabeth Arden Co., Division of Conopco, Inc.Inventors: Stewart Paton Granger, Anthony Vincent Rawlings, Ian Richard Scott
-
Patent number: 5885974Abstract: Methods are disclosed for correcting biological information transfer in a patient in need of such therapy which comprise administration to a patient of a composition comprising a therapeutically effective amount of a biocomplex comprising at least one bioactive agent from each of the three informational blocks of biological information transfer, each agent being present in an amount sufficient to correct the biological information transfer of the patient under treatment and resulting in the resumption of normal cell metabolism, said amount being less than the buffering amount of said agent; together with a carrier therefor.Type: GrantFiled: December 6, 1994Date of Patent: March 23, 1999Assignee: Michael M. DanielovInventor: Michael M. Danielov
-
Patent number: 5760022Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises an aliphatic ester or ether for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one aliphatic ester or ether compound for the preparing of an inositol phosphate containing medicament with improved bioavailability of inositol phosphate in mammals including man at non-parenteral administration.Type: GrantFiled: July 17, 1996Date of Patent: June 2, 1998Assignee: Perstorp ABInventors: Lars Persson, Torgny Gustafsson, Nicola Rehnberg
-
Patent number: 5753634Abstract: Disclosed are quaternary nitrogen-containing, saturated or unsaturated monocyclic and bicyclic ring-containing bisphosphonate compounds, and pharmaceutically-acceptable salts and esters thereof. These compounds, which are useful for treating or preventing disorders of calcium and phosphate metabolism, have the following general structure: ##STR1## wherein (a) each X and Y are independently selected from nil, O, S, NR.sup.1 and N.sup.+ (R.sup.2).sub.2 ; if no R.sup.1 is N.sup.+ (R.sup.2).sub.2, then at least one of X or Y must be N.sup.+ (R.sup.2).sub.2 ;(b) m and n and m+n are integers from 0 to 5; p and q and p+q are integers from 0 to 3;(c) s is an integer from 0 to 2 and when m+n=0 and X is nil, s=2;(d) each R.sup.1 is independently selected from the group consisting of nil, N.sup.+ (R.sup.2).sub.2, R.sup.9 SR.sup.6, SR.sup.6, hydrogen, hydroxy; unsubstituted or substituted C.sub.1 -C.sub.8 alkyl, --OR.sup.3, --CO.sub.2 R.sup.3, --O.sub.2 CR.sup.3, NR.sup.3.sub.2, --N(R.sup.3)C(O)R.sup.3, --C(O)N(R.sup.3).Type: GrantFiled: April 30, 1993Date of Patent: May 19, 1998Assignee: The Procter & Gamble CompanyInventors: Frank Hallock Ebetino, Marion David Francis, Susan Mary Kaas
-
Patent number: 5733478Abstract: A method for reducing the rate of degradation of stored agrochemicals, particularly pesticides, is provided which essentially involves incorporating a stabilizing compound into the agrochemical in preparation for storage, with the stabilizing compound selected from the group consisting of a diol and a triol. In the preferred embodiment, a pesticide having the active ingredient METASYSTOX.RTM. has an improved shelf life with the addition of about 2 parts by weight of propylene glycol to about 25 parts by weight of METASYSTOX.RTM..Type: GrantFiled: September 24, 1996Date of Patent: March 31, 1998Assignee: Gowan CompanyInventors: David C. Creech, James P. Glatzhofer, Shane A. Wyatt
-
Patent number: 5728731Abstract: The oligomers of the present invention are polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: June 6, 1995Date of Patent: March 17, 1998Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical Co.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5709890Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.Type: GrantFiled: March 20, 1997Date of Patent: January 20, 1998Assignee: Donlar CorporationInventor: J. Larry Sanders
-
Patent number: 5646133Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.Type: GrantFiled: March 14, 1996Date of Patent: July 8, 1997Assignee: Donlar CorporationInventor: J. Larry Sanders
-
Patent number: 5614510Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises a nitrogen-containing compound for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one nitrogen-containing compound for the preparing of an inositol phosphate containing medicament with improved bioavailibility of inositol phosphate in mammals including man at non-parenteral administration.Type: GrantFiled: August 22, 1994Date of Patent: March 25, 1997Assignee: Perstorp ABInventor: Lars Persson
-
Patent number: 5500416Abstract: A percutaneous absorption promoting agent comprising (A) at least one anionic surfactant and one or two or more of surfactants having a nitrogen atom in the molecule other than anionic surfactants, (B) one or two or more of anionic surfactants and one or two or more of nonionic surfactants not having a nitrogen atom in the molecule, (C) one or two or more of surfactants selected from the group consisting of amphoteric surfactant and semi-polar surfactants and at least one nonionic surfactant having a nitrogen atom in the molecule, (D) one or two or more of surfactants selected from the group consisting of nonionic surfactants, amphoteric surfactants, semi-polar surfactants and cationic surfactants having a nitrogen atom in the molecule, and one or two or more of nonionic surfactants not having a nitrogen atom in the molecule, or (E) an amine oxide as the active ingredient, and a dermatological preparation containing these percutaneous absorption promoting agent and drug components.Type: GrantFiled: September 10, 1993Date of Patent: March 19, 1996Assignee: Shiseido Company Ltd.Inventors: Kiyoshi Miyazawa, Tadahiro Chiba, Yuhei Iwata, Uhei Tamura, Isao Murotani, Shuya Tamaki
-
Patent number: 5342832Abstract: A method of preventing or alleviating tissue damage, diabetes and complications thereof, bone disorders, disorders related to transplantation, disorders related to abnormal levels of lipoproteins, cardiovascular disease and inflammatory disorders by providing a mammal having one or more of the above diseases with a preventing or an alleviating effective amount of a compound having the formula C.sub.6 H.sub.6 (OH).sub.6-n (OPO.sub.3 H.sub.2).sub.n, where n is an integer of 1 or 2.Type: GrantFiled: August 21, 1992Date of Patent: August 30, 1994Assignee: Perstorp ABInventor: Matti Siren
-
Patent number: 5208223Abstract: Phospocholine derivatives having the formula: ##STR1## in which W, Z, Q and R are described in the specification are disclosed as useful for inhibiting the enzyme phospholipase A.sub.2. Methods of making and using the compounds are also disclosed.Type: GrantFiled: June 3, 1992Date of Patent: May 4, 1993Assignee: American Cyanamid CompanyInventors: Allan Wissner, Robert E. Schaub, Kenneth E. Green, Philip R. Hamann
-
Patent number: 5167947Abstract: The present invention provides a pharmaceutical composition for enhancing gastrointestinal tract absorption of a radioprotective drug comprising a therapeutically effective dosage amount of a bioactive polar radioprotective agent, such as ethiofos, its active metabolites, and pharmaceutically acceptable salts thereof and a chelating agent selected from the group consisting of EDTA, EGTA, citrate and therapeutically acceptable salts thereof.A method for enhancing the rate of gastrointestinal absorption of radioprotective agents is also provided.Type: GrantFiled: October 26, 1989Date of Patent: December 1, 1992Assignee: Southwest Research InstituteInventor: Richard Geary
-
Patent number: 5140019Abstract: Compositions which contain, as the active ingredients, a combination of heterocyclic compounds of the general formula (I) and organophosphorous compounds, in addition to one or more compounds having a polyethyleneglycol or polypropyleneglycol chain or an ethyleneglycol-propyleneglycol copolymeric chain, or a mixture of these compounds which results in a stabilization of the active ingredients without any adverse influences on the physical properties of the formulations.Type: GrantFiled: November 19, 1990Date of Patent: August 18, 1992Assignee: Nihon Tokushu Noyaku Seizo K.K.Inventors: Yuzuru Wada, Shigeharu Koyama
-
Patent number: 5120716Abstract: A percutaneous absorption promoting agent comprising (A) at least one anionic surfactant and one or two or more of surfactants having a nitrogen atom in the molecule other than anionic surfactants, (B) one or two or more of anionic surfactants and one or two or more of nonionic surfactants not having a nitrogen atom in the molecule, (C) one or two or more of surfactants selected from the group consisting of amphoteric surfactant and semi-polar surfactants and at least one nonionic surfactant having a nitrogen atom in the molecule, (D) one or two or more of surfactants selected from the group consisting of nonionic surfactants, amphoteric surfactants, semi-polar surfactants and cationic surfactants having a nitrogen atom in the molecule, and one or two or more of nonionic surfactants not having a nitrogen atom in the molecule, or (E) an amine oxide as the active ingredient, and a dermatological preparation containing these percutaneous absorption promoting agent and drug components.Type: GrantFiled: October 5, 1988Date of Patent: June 9, 1992Assignee: Shiseido Company Ltd.Inventors: Kiyoshi Miyazawa, Tadahiro Chiba, Yuhei Iwata, Uhei Tamura, Isao Murotani, Shuya Tamaki
-
Patent number: 4975424Abstract: The present invention relates to a method for stabilizing a thiophosphoric acid ester of the formula (I), ##STR1## wherein R is a methyl or ethyl group, by adding at least one compound selected from the group consisting of polyols, polyalkylene glycols and their esters and ethers.According to the present invention, there is provided a highly active and stable soil pest controlling agent and agricultural composition.Type: GrantFiled: April 28, 1989Date of Patent: December 4, 1990Assignee: Sumitomo Chemical Company, LimitedInventor: Masao Ogawa
-
Patent number: 4935408Abstract: A compound of the formula: ##STR1## in which R.sup.1 represents alkyl, cycloalkyl or aralkyl, R* represents fluorophenyl or trifluoromethylphenyl when R.sup.1 is alkyl; R* represents dichlorophenyl, neopentyl, trimethylsilylmethyl, dimethylphenylsilylmethyl or a group of the formula: ##STR2## wherein R.sup.2 represents halogen, trifluoromethyl, lower alkyl or lower alkoxy when R.sup.1 is cycloalkyl; or R* represents 2-thienyl, 3-thienyl, neopentyl, trimethylsilylmethyl, dimethylphenylsilylmethyl or a group of the formula: ##STR3## wherein R.sup.3, R.sup.4 and R.sup.5 independently represent halogen, trifluoromethyl, lower alkyl or lower alkoxy when R.sup.1 is aralkyl, m represents 1 or 2, and X represents halogen, imidazolyl, triazolyl, phenylthio or a radical selected from the group consisting of: ##STR4## wherein R.sup.6 represents alkyl, R.sup.7 and R.sup.8 independently represent lower alkyl and R.sup.9 and R.sup.Type: GrantFiled: May 6, 1988Date of Patent: June 19, 1990Assignees: Shionogi & Co., Ltd., Nitto Kasei Co., Ltd.Inventors: Hideyuki Imazaki, Masazumi Fujikawa, Katsuaki Oba, Fusaharu Kumayama, Toshio Takahashi
-
Patent number: 4855140Abstract: O-(O-ethyl-S-alkylphosphoryl)-O-(carbamoyl)-pyrocatechol derivatives of the formula I ##STR1## where R.sup.1 is C.sub.1 -C.sub.4 -alkyl, R.sup.2 is hydrogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, R.sup.3 is hydrogen or C.sub.1 -C.sub.4 -alkyl, and X is oxygen or sulfur, and methods of combating pests with effective amounts of I.Type: GrantFiled: September 26, 1988Date of Patent: August 8, 1989Assignee: BASF AktiengesellschaftInventors: Wolfgang Seppelt, Linhard Sproesser, Siegfried Kersten, Peter Hofmeister, Christoph Kuenast
-
Patent number: 4774235Abstract: A compound of the formula: ##STR1## in which R.sup.1 represents alkyl, cycloalkyl or aralkyl, R* represents fluorophenyl or trifluoromethylphenyl when R.sup.1 is alkyl; R* represents dichlorophenyl, neopentyl, trimethylsilylmethyl, dimethylphenylsilylmethyl or a group of the formula: ##STR2## wherein R.sup.2 represents halogen, trifluoromethyl, lower alkyl or lower alkoxy when R.sup.1 is cycloalkyl; or R* represents 2-thienyl, 3-thienyl, neopentyl, trimethylsilylmethyl, imethylphenylsilylmethyl or a group of the formula: ##STR3## wherein R.sup.3, R.sup.4 and R.sup.5 independently represent hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy when R.sup.1 is aralkyl, m represents 1 or 2, and X represents halogen, imidazolyl, triazolyl, phenylthio or a radical selected from the group consisting of: ##STR4## wherein R.sup.6 represents alkyl, R.sup.7 and R.sup.8 independently represent lower alkyl and R.sup.9 and R.sup.Type: GrantFiled: August 21, 1986Date of Patent: September 27, 1988Assignees: Shionogi & Co., Ltd., Nitto Kasei Co., Ltd.Inventors: Hideyuki Imazaki, Masazumi Fujikawa, Katsuaki Oba, Fusaharu Kumayama, Toshio Takahashi